Hepatitis B vaccine and risk of relapse after a first childhood episode of CNS inflammatory demyelination

Brain

Volumn 130, Issue 4, 2007, Pages 1105-1110

  Mikaeloff, Yann ^a   Caridade, Guillaume ^a   Assi, Saada ^a   Tardieu, Marc ^c   Suissa, Samy ^b  

^a BICÊTRE HOSPITAL   (France)

^b ROYAL VICTORIA HOSPITAL   (Canada)

^c Assistance Publique Hôpitaux de Paris ^*

Author keywords

Child; Epidemiology; Hepatitis B vaccine; Immune mediated demyelination; Multiple sclerosis

Indexed keywords

HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE; TETANUS TOXOID;

ADOLESCENT; ARTICLE; CHILD; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CONTROLLED STUDY; EXPOSURE; FEMALE; FOLLOW UP; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE; RISK FACTOR; STATISTICAL MODEL; TETANUS PROPHYLAXIS; VACCINATION; ACUTE DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; COMPARATIVE STUDY; DEMYELINATING DISEASE; HEPATITIS B; IMMUNOLOGY; MYELITIS; ONSET AGE; PRESCHOOL CHILD; RECURRENT DISEASE; RISK; TETANUS;

ACUTE DISEASE; AGE OF ONSET; CENTRAL NERVOUS SYSTEM DISEASES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DEMYELINATING AUTOIMMUNE DISEASES, CNS; DEMYELINATING DISEASES; FEMALE; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; INFANT; MALE; MULTIPLE SCLEROSIS; MYELITIS, TRANSVERSE; ODDS RATIO; RECURRENCE; RISK FACTORS; TETANUS; TETANUS TOXOID;

EID: 34249701674     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awl368     Document Type: Article

References (25)

1. Ascherio A, Zhang SM, Hernan MA, Olek MJ, Coplan PM, Brodovicz K, et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001; 344: 327-32.
2. Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997; 120: 2059-69.
3. Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359: 1221-31.
4. Confavreux C, Suissa S, Saddier P, Bourdès V, Vukusic S. Vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med 2001; 344: 319-26.
5. Chen RT, Davis RL, Rhodes PH. Special methodological issues in pharmacoepidemiology studies of vaccine safety. In: Strohm BL, editor. Pharmacoepidemiology. Chichester: John Wiley & Sons; 2005. p. 455-85.
6. Denis F. Hepatitis B vaccination in France: vaccination coverage in 2002. Bull Acad Natl Med 2004; 188: 115-23.
7. DeStefano F, Verstraeten T, Jackson LA, Okoro CA, Benson P, Black SB, et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol 2003; 60: 504-9.
8. DeStefano F, Weintraub ES, Chen RT. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology 2005; 64: 1317.
9. Hernan MA, Jick SS, Olek MJ, Jick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology 2004; 63: 838-42.
10. Hernan MA, Jick SS. Hepatitis B vaccination and multiple sclerosis: the jury is still out. Pharmacoepidemiol Drug Saf 2006; 15: 653-5.
11. INSEE. Nomenclature des professions et catégories professionnelles 2003. Paris: INSEE, 2003.
12. Kane M, Clements J, Hu D, Hepatitis B. In: Jamison DT, Mosley WH, Measham AR, Bobadilla JL, editors. Disease control priorities in developing countries. New York: Oxford University Press; 1993. p. 321-30.
13. Mikaeloff Y, Suissa S, Vallée L, Lubetzki C, Ponsot G, Confavreux C, et al. First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. J Pediatr 2004a; 144: 246-52.
14. Mikaeloff Y, Adamsbaum C, Husson B, Vallée L, Ponsot G, Confavreux C, et al. MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. Brain 2004b; 127: 1942-7.
15. Mikaeloff Y, Caridade G, Assi S, Suissa S, Tardieu M. Prognostic factors for early severity in a childhood multiple sclerosis cohort. Pediatrics 2006; 118: 1133-9.
16. Naismith RT, Cross AH. Does the hepatitis B vaccine cause multiple sclerosis? Neurology 2004; 63: 772-3.
17. Piaggio E, Ben Younes A, Desbois S, Gout O, Tourbah A, Lyon-Caen O, et al. Hepatitis B vaccination and central nervous system demyelination: an immunological approach. J Autoimmun 2005; 24: 33-7.
18. Rutschmann OT, McCrory DC, Matchar DB. Immunization and MS: a summary of published evidence and recommendations. Neurology 2002; 59: 1837-43.
19. Sadovnick AD, Scheifele DW. School-based hepatitis B vaccination programme and adolescent multiple sclerosis. Lancet 2000; 355: 549-50.
20. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med 2003; 168: 49-53.
21. Suissa S. Inhaled steroids and mortality in COPD: bias from unaccounted immortal time. Eur Respir J 2004; 23: 391-5.
22. Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine 2005; 23: 3876-86.
23. Strom BL, editor. Pharmacoepidemiology. Chichester: John Wiley & Sons; 2005.
24. Touze E, Fourrier A, Rue-Fenouche C, Ronde-Oustau V, Jeantaud I, Begaud B, et al. Hepatitis B vaccination and first central nervous system demyelinating event: a case-control study. Neuroepidemiology 2002; 21: 180-6.
25. Zipp F, Weil JG, Einhaupl KM. No increase in demyelinating diseases after hepatitis B vaccination. Nat Med 1999; 5: 964-5.